The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1485
Eluxadoline (Viberzi) for Irritable Bowel Syndrome with Diarrhea
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved eluxadoline (Viberzi – Actavis), a mu-opioid receptor agonist and delta-opioid receptor antagonist, for oral treatment of adults with irritable bowel syndrome with diarrhea (IBS-D).

IBS — Symptoms of IBS can include abdominal pain, bloating, flatulence, diarrhea, and constipation. IBS is subtyped, according to the predominant bowel symptom, as IBS-D, IBS with constipation (IBS-C), mixed-type (IBS-M), or unclassified (IBS-U).

SOME DRUGS FOR IBS-D — The goal of IBS treatment is symptom control; dietary modifications may help improve symptoms of all subtypes of the disorder. For patients with IBS-D, antidiarrheals such as loperamide (Imodium A-D, and others) taken as needed may reduce stool urgency and frequency. In short-term clinical trials, the minimally absorbed antibiotic rifaximin (Xifaxan) was modestly more effective than placebo in ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Eluxadoline (Viberzi) for Irritable Bowel Syndrome with Diarrhea
Article code: 1485c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian